Every earnings call announcement on NSE and BSE that our alert engine sent, newest first. Each one has its own page with the summary, the key figures and the original filing.
Q2FY27 revenue INR 44.7bn (+18% YoY), Adj. EBITDA INR 16.1bn (36.2% margin), PAT INR 10.1bn (+28%, 22.1% margin). Strategy targets ~20% PAT CAGR to FY31 with net D/E at or below 0.5x.
Skipper delivered record Q2 revenue but growth slowed to 10%, necessitating a sharp 21%+ H2 ramp-up. Export diversification into US/Australia is offsetting Middle East geopolitical volatility.
Consolidated revenue grew 20% YoY on 14% SSSG, with company EBITDA rising sharply on restaurant margin gains. Indonesia is near restaurant-level break-even, but management gave no quantified forward guidance.
RPG Life Sciences delivered record quarterly revenue exceeding ₹200 Cr, driven by volume-led growth in domestic formulations and strategic API acquisitions. Management maintains a focus on premiumization and operational efficiency despite West Asia supply headwinds.
Q2 FY27 income from operations rose 18.52% YoY to ₹898.87L and AUM rose 17.35% to ₹12,192.35L, but PBT grew only 5.40% to ₹550.21L. Strategy centres on digital consumer durable loans and a planned loan-against-securities (LAS) platform.
PNG Jewellers delivered a robust performance with 22% revenue growth, driven by strategic expansion in UP and a richer product mix (higher stud ratio).
Ajanta Pharma posted robust revenue and PAT growth, primarily driven by a temporary US market upside. Management remains cautious as competition intensifies.
Q2 FY27 standalone: PAT Rs1,798Mn (+56% YoY) on consultancy segment profit +58%; total income -7% as turnkey revenue fell 58%. Order book Rs204,205Mn (+56% YoY).